References
- Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms – an update on the multidisciplinary management of malignant glioma. Oncologist 2006;11:165-80
- De Rosa G, Salzano G, Caraglia M, et al. Nanotechnologies: a strategy to overcome blood–brain barrier. Curr Drug Metab 2012;13:61-9
- Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40
- Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5
- Taal W, Oosterkamp HM, Walenkamp AME, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. American Society for Clinical Oncology (ASCO), Chicago, IL, USA, 1 June 2013, Abstract #2001
- Addeo R, De Santi MS, Del Prete S, et al. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer Chemother Pharmacol 2009;64:863-6
- Soffietti R, Ruda R, Trevisan E. Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: a multicenter Italian study (abstract 2012). J Clin Oncol 2009;27:90s
- Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GLIOBLASTOMA). J Clin Oncol 2013;31:Suppl(Abstr 1)
- Wick W, Cloughesy TF, Nishikawa R, et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GLIOBLASTOMA). J Clin Oncol 2013;31:Suppl(Abstr 2002)
- Wong ET, Gautam S, Malchow C, et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 2011;9:403-7
- Caraglia M, De Rosa G, Salzano G, et al. Nanotech revolution for the anti-cancer drug delivery through blood–brain barrier. Curr Cancer Drug Targets 2012;12:186-96